Peptides for Inflammation & Pain Management Research

NSAIDs (non-steroidal anti-inflammatory drugs) work by blocking COX enzymes, which reduces prostaglandin production but also impairs the healing process and carries significant side effects including gastric ulceration and cardiovascular risk. BPC-157 and TB-500 operate through fundamentally different mechanisms — they modulate inflammatory signalling pathways (including NF-kB and cytokine expression) while simultaneously promoting tissue repair. BPC-157 actually protects the gastric mucosa rather than damaging it. This represents a paradigm shift in inflammation research: instead of simply suppressing the inflammatory response, these peptides aim to resolve it while accelerating the underlying healing process.

Oxidative stress and chronic inflammation form a self-perpetuating cycle. Inflammatory cells generate reactive oxygen species (ROS) as part of the immune response. When inflammation becomes chronic, excessive ROS damages surrounding tissue, which triggers further inflammation, creating a destructive feedback loop. Glutathione breaks this cycle by neutralising ROS and supporting the resolution phase of inflammation. As the body's most abundant intracellular antioxidant, Glutathione directly scavenges free radicals, regenerates other antioxidants like vitamins C and E, and supports immune cell regulation. Peptides Pharma's vial-delivered Glutathione provides maximum bioavailability to address systemic oxidative burden.

BPC-157 is uniquely suited for gut inflammation research because it is derived from a protein naturally found in human gastric juice. Published studies in animal models demonstrate its efficacy in inflammatory bowel disease, gastric ulcers, NSAID-induced intestinal damage, and oesophageal inflammation. Its mechanisms include promoting mucosal blood flow via nitric oxide pathways, stimulating growth factor expression for epithelial repair, and modulating inflammatory cytokines in the GI microenvironment. Unlike many anti-inflammatory compounds that can damage the gut lining, BPC-157 actively protects and repairs it.

TB-500 (Thymosin Beta-4 fragment) adds a unique dimension to anti-inflammatory research. While BPC-157 focuses on promoting tissue repair and angiogenesis at inflammation sites, TB-500 specifically promotes the migration of anti-inflammatory and reparative cells into damaged tissue by upregulating actin polymerisation. TB-500 also directly modulates NF-kB signalling — the master transcription factor controlling inflammatory gene expression — and reduces the production of pro-inflammatory cytokines like IL-1beta and TNF-alpha. This complementary mechanism means that BPC-157 creates the conditions for healing while TB-500 actively recruits the cellular machinery to execute it.